Entity

Time filter

Source Type

Murviel-lès-Montpellier, France

Lacombe J.,Montpellier University | Lacombe J.,Laboratoire dOncoproteomique Clinique | Mange A.,Montpellier University | Mange A.,Laboratoire dOncoproteomique Clinique | And 4 more authors.
Cancer/Radiotherapie | Year: 2013

The success of radiotherapy mainly depends on the total administered dose. This dose must be homogenously delivered onto the tumor and must preserve the surrounding healthy tissue. However, several patients are hypersensitive to ionizing radiations and may develop important radiation-induced early and late side effects. The prediction of these side effects remains currently impossible, involving to limit the given dose with the risk to decrease the therapeutic benefit for patients. Therefore, one of the major challenges in radiobiology is to accurately predict tumour radioresistance and to determine normal tissue radiosensitivity to tailor treatment. Several studies have been carried out and different predictive assays have been described in this field. However, none of them showed significant results for clinical use. For several years, many technological advances in proteomic fields have been performed in order to identify new biomarkers. After a brief description of the main characteristics of tumor radioresistance and normal tissue radiosensitivity, we will develop in this review the different approaches proposed so far to identify predictive tools of radiotherapy outcome. We will then analyze in detail how proteomic studies can improve the understanding of mechanisms associated with radiosensitivity of healthy tissue and radioresistance of tumor cells and how they could highlight new predictive biomarkers in radiobiology. © 2012 . Source


Desmetz C.,Montpellier University Hospital Center | Desmetz C.,Laboratoire dOncoproteomique Clinique | Desmetz C.,Montpellier University | Mange A.,Montpellier University Hospital Center | And 8 more authors.
Journal of Cellular and Molecular Medicine | Year: 2011

Introduction • Unknown origins of autoantibody production in cancer • The use of proteomics to identify autoantibodies • Clinical utility of autoantibody signatures for early detection of cancer - Autoantibodies as potential cancer biomarkers - Defining autoantibody signatures in cancer: still many challenges • Autoantibody detection to build screening tests in high-risk populations • Conclusion and perspectives Becoming invasive is a crucial step in cancer development, and the early spread of tumour cells is usually undetected by current imaging technologies. In patients with cancer and no signs of overt metastases, sensitive methods have been developed to identify circulating autoantibodies and their antigen counterparts in several cancers. These technologies are often based on proteomic approaches, and recent advances in protein and antibody microarrays have greatly facilitated the discovery of new antibody biomarkers in sera from cancer patients. Interestingly, in a clinical application setting, combinations of multiple autoantibody reactivities into panel assays have recently been proposed as relevant screening tests and validated in several independent trials. In addition, autoantibody signatures seem to be particularly relevant for early detection of cancer in high-risk cancer patients. In this review, we highlight the concept that immunogenic epitopes associated with the humoural response and key pathogenic pathways elicit serum autoantibodies that can be considered as relevant cancer biomarkers. We outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures in several cancers. Finally, we discuss the challenges remaining for clinical validation. © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. Source


Desmetz C.,Montpellier University Hospital Center | Desmetz C.,Laboratoire dOncoproteomique Clinique | Desmetz C.,Montpellier University | Lacombe J.,Montpellier University Hospital Center | And 11 more authors.
Medecine/Sciences | Year: 2011

It is now well established that an immune response to cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer. During these past few years, proteomic approaches have been developed to identify tumor-associated antigens and their cognate autoantibodies. Detection of a panel of serum autoantibodies has thus been proposed as a new method for early cancer diagnosis. Early detection seems to be particularly adequate in high-risk populations, such as heavy smokers for lung cancer or in women with high mammographic density for breast cancer. In this review, we highlight the features of serum autoantibody biomarkers and outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures, using the examples of lung and breast cancer. Finally, we discuss the challenges remaining for clinical validation. 0. Source

Discover hidden collaborations